Related Experiment Video
Updated: Jan 21, 2026
07:58
Laboratory Techniques Used to Maintain and Differentiate Biotypes of Vibrio cholerae Clinical and Environmental Isolates
Published on: May 30, 2017
11.5K
Clinical Use of Polymyxin B
Maria Helena Rigatto1,2, Diego R Falci3,4, Alexandre P Zavascki5,6
1Infectious Diseases Service, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Advances in Experimental Medicine and Biology
|August 1, 2019
Summary
Polymyxin B is a crucial antibiotic for treating multidrug-resistant Gram-negative bacterial infections. This review examines clinical and microbiological outcomes in patients treated with Polymyxin B, highlighting its re-emergence in clinical practice.
Area of Science:
- Pharmacology and Infectious Diseases
- Antimicrobial Resistance Research
Background:
- Polymyxin B is clinically utilized for infections caused by multidrug- (MDR) or extensively-drug-resistant (XDR) Gram-negative bacteria (GNB).
- Polymyxin B shares structural similarity with Polymyxin E (colistin), but pharmacokinetic differences exist due to colistin's prodrug administration.
- These pharmacokinetic variations may influence clinical and microbiological outcomes.
Purpose of the Study:
- To review studies on clinical and microbiological outcomes in patients treated with Polymyxin B for MDR or XDR GNB infections.
- To provide insights into the efficacy and application of Polymyxin B in contemporary clinical practice.
Main Methods:
- Literature review of studies focusing on Polymyxin B treatment for MDR/XDR GNB.
- Analysis of clinical and microbiological outcomes reported in the selected studies.
Main Results:
- Polymyxin B has re-emerged as a vital therapeutic option for challenging Gram-negative bacterial infections.
- The review synthesizes existing data on the effectiveness of Polymyxin B in diverse patient populations and infection types.
- Key clinical and microbiological parameters associated with Polymyxin B therapy are discussed.
Conclusions:
- Polymyxin B remains an important agent in the armamentarium against MDR/XDR GNB.
- Understanding its clinical and microbiological impact is crucial for optimizing treatment strategies.
- Further research may elucidate specific scenarios where Polymyxin B offers superior outcomes compared to other agents.
Related Concept Videos
01:27Nursing Clinical Information System
1.2K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.2K
01:16Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:14Changes in Skin Color: Clinical Perspectives
3.3K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
3.3K
01:20COPD: Pathogenesis and Clinical Features
1.8K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.8K
01:28Esophageal Perforation-II: Clinical Manifestations and Management
523
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Clinical Manifestations:
523